Pelvic mesh or transvaginal mesh devices are most commonly used to treat conditions caused by weakened pelvic muscles, such as pelvic organ prolapse (POP) or stress urinary incontinence (SUI). Although pelvic mesh implantation is less invasive than some treatments for SUI and POP, the complication rate is much higher, often requiring revision surgery. After reviewing post-market studies and patient data, the Food and Drug Administration (FDA) stated that serious complications related to pelvic mesh were not rare and the device is no more effective at treating prolapse than non-mesh treatments.  In April 2019, the FDA ordered manufacturers of all remaining transvaginal mesh devices for POP repair to stop selling their products immediately.